Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright

Harmony Biosciences (NASDAQ:HRMY)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday, Marketbeat.com reports. They currently have a $55.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 48.53% from the company’s previous close.

Other research analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Harmony Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 16th. Oppenheimer reiterated an “outperform” rating on shares of Harmony Biosciences in a research report on Thursday, September 24th. Wolfe Research initiated coverage on Harmony Biosciences in a research note on Wednesday, August 26th. They set an “outperform” rating and a $60.00 price target on the stock. Truist Financial upped their price target on Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $37.00 price objective on shares of Harmony Biosciences in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $47.44.

Harmony Biosciences Price Performance

Harmony Biosciences stock traded down $1.20 during midday trading on Tuesday, reaching $37.03. The company’s stock had a trading volume of 1,418,867 shares, compared to its average volume of 867,891. The firm has a market capitalization of $2.16 billion, a PE ratio of 12.02, a P/E/G ratio of 0.32 and a beta of 1.01. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $43.49. The stock’s 50 day simple moving average is $40.13 and its 200 day simple moving average is $35.12. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.32. The business had revenue of $261.28 million for the quarter, compared to analysts’ expectations of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. The business’s revenue for the quarter was up 30.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 EPS. On average, equities research analysts forecast that Harmony Biosciences will post 3.79 earnings per share for the current year.

Insider Buying and Selling

In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the completion of the transaction, the insider directly owned 13,115 shares in the company, valued at approximately $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have sold 72,406 shares of company stock valued at $3,108,520. 11.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Harmony Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Harmony Biosciences during the 2nd quarter worth approximately $258,583,000. Dimensional Fund Advisors LP grew its holdings in Harmony Biosciences by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock valued at $58,157,000 after buying an additional 245,784 shares during the last quarter. SG Americas Securities LLC grew its holdings in Harmony Biosciences by 109.9% during the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock valued at $56,529,000 after buying an additional 1,056,507 shares during the last quarter. Renaissance Technologies LLC increased its position in Harmony Biosciences by 0.6% during the first quarter. Renaissance Technologies LLC now owns 1,077,371 shares of the company’s stock worth $30,177,000 after buying an additional 6,900 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Harmony Biosciences during the fourth quarter worth $18,710,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Key Headlines Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Analysts reaffirm bullish views: HC Wainwright reiterated its “buy” rating and set a $55 price target, implying approximately 48% upside from the referenced $37.06 share price. Needham also reaffirmed its “buy” rating with a $50 target, representing roughly 35% potential upside. These targets indicate that both firms expect continued growth from Harmony’s commercial business and pipeline. HC Wainwright rating report Needham rating report
• Neutral Sentiment: Planned CEO transition creates both continuity and execution considerations: Harmony announced that COO Peter Anastasiou will become president and CEO as part of its next growth phase, while current leadership is expected to remain involved. The promotion could support operational continuity, but investors may initially scrutinize the transition’s impact on strategy, product expansion and execution. Harmony CEO promotion article Harmony planned CEO transition announcement
• Neutral Sentiment: A financial comparison between PainReform and Harmony Biosciences provides limited direct information about HRMY’s near-term outlook and is unlikely to be a major stock catalyst. PainReform and Harmony financial comparison
• Negative Sentiment: Bank of America remains bearish: The firm maintained its “sell” rating on Harmony Biosciences, countering the positive views from HC Wainwright and Needham. The conflicting analyst outlook may be contributing to pressure on the shares and highlights continued investor concerns despite Harmony’s strong recent earnings and revenue growth. Bank of America sell rating article

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial-stage pharmaceutical company focused on developing and marketing therapies for patients with rare neurological disorders. The company’s activities center on conditions that are often underserved by conventional treatment options, including sleep disorders and other central nervous system diseases.

Harmony’s principal product is WAKIX (pitolisant), an oral, non-scheduled medication that acts as a histamine-3 receptor antagonist/inverse agonist.